A novel Elecsys immunoassay that can detect the level of plasma Aβ automatically can improve the accuracy of prescreening Aβ in clinical AD trials with the combination of blood APOE detection, which can be used to reduce costs and the number of PET/lumbar punctures.112. The gene discussed is APOE; the disease is Alzheimer disease.